A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus

OBJECTIVE: To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE) beyond 1 year. METHODS: This was a 24-week, open-label extension following a 52-week, double-blind, placebo-controlled trial of belimumab SC. Patients who c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lupus
Asıl Yazarlar: Doria, A, Bass, D, Schwarting, A, Hammer, A, Gordon, D, Scheinberg, M, Fox, N L, Groark, J, Stohl, W, Kleoudis, C, Roth, D
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2018
Konular:
Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6066857/
https://ncbi.nlm.nih.gov/pubmed/29807477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203318777634
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller